New York Life Investment Management LLC lowered its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 13.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,630 shares of the company’s stock after selling 2,003 shares during the quarter. New York Life Investment Management LLC’s holdings in Alkermes were worth $354,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Signaturefd LLC lifted its position in shares of Alkermes by 121.2% in the second quarter. Signaturefd LLC now owns 854 shares of the company’s stock valued at $27,000 after acquiring an additional 468 shares in the last quarter. Emerald Advisers LLC purchased a new position in Alkermes in the 3rd quarter valued at about $27,000. Neo Ivy Capital Management acquired a new stake in shares of Alkermes during the 2nd quarter worth about $27,000. CWM LLC grew its holdings in shares of Alkermes by 147.5% during the third quarter. CWM LLC now owns 1,037 shares of the company’s stock worth $29,000 after buying an additional 618 shares in the last quarter. Finally, Castleview Partners LLC acquired a new position in shares of Alkermes in the second quarter valued at approximately $38,000. Institutional investors and hedge funds own 95.21% of the company’s stock.
Alkermes Stock Performance
Alkermes stock opened at $28.52 on Tuesday. The company has a market cap of $4.76 billion, a PE ratio of 23.00 and a beta of 0.55. The company has a fifty day moving average price of $27.62 and a two-hundred day moving average price of $27.31. Alkermes plc has a 12 month low of $22.01 and a 12 month high of $33.71. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.91 and a quick ratio of 2.53.
Analysts Set New Price Targets
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer.
- Five stocks we like better than Alkermes
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 attractive stocks that insiders are buying
- The Most Important Warren Buffett Stock for Investors: His Own
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to invest in blue chip stocks
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.